Racial variability in the UDP-glucuronosyltransferase 1 ( UGT1A1 ) promoter: A balanced polymorphism for regulation of bilirubin metabolism?
Open accessThe DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.
Abstract
A polymorphism in the promoter of the UDP-glucuronosyltransferase 1 ( UGT1A1 ) gene has been shown to cause Gilbert syndrome, a benign form of unconjugated bilirubinemia. Promoters containing seven thymine adenine (ta) repeats have been found to be less active than the wild-type six repeats, and the serum bilirubin levels of persons homozygous or even heterozygous for seven repeats have been found to be higher than those with the wild-type six repeats. We have now examined the genotypes in persons of Asian, African, and Caucasian ancestry. Although within the Caucasian ethnic group there is a strong correlation between promoter repeat number and bilirubin level, between ethnic groups we found that this relationship to be inverse. Among people of African ancestry there are, in addition to those with six and seven repeats, also persons who have five or eight repeats. Using a reporter gene we show that there is an inverse relationship between the number of ta repeats and the activity of the promoter through the range of 5–8 ta repeats. An incidental finding was a polymorphism at nucleotide −106, tightly linked to the (ta) 5 haplotype. Serum bilirubin levels are influenced by many factors, both genetic and environmental. We suggest that the unstable UGT1A1 polymorphism may serve to “fine-tune” the plasma bilirubin level within population groups, maintaining it at a high enough level to provide protection against oxidative damage, but at a level that is sufficiently low to prevent kernicterus in infants.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Bilirubin Is an Antioxidant of Possible Physiological Importance
Stocker, R., Yamamoto, Y., McDonagh, A. F., Glazer, A. N., & Ames, B. N. (1987) · Science · doi:10.1126/science.3029864 · Cited by 2,948
Bosma, P. J., Chowdhury, J. R., Bakker, C., Gantla, S., de Boer, A., Oostra, B. A., Lindhout, D., Tytgat, G. N. J., Jansen, P. L. M., Elferink, R. P. J. O., et al. (1995) · New England Journal of Medicine · doi:10.1056/nejm199511023331802 · Cited by 1,447
Mackenzie, P. I., Owens, I. S., Burchell, B., Bock, K. W., Bairoch, A., Belanger, A., Gigleux, S. F., Green, M., Hum, D. W., Iyanagi, T., et al. (1997) · Pharmacogenetics · doi:10.1097/00008571-199708000-00001 · Cited by 1,183
Genetic variation in bilirubin UDP-glucuronosyltransferase gene promoter and Gilbert's syndrome
Monaghan, G., Ryan, M., Hume, R., Burchell, B., & Seddon, R. (1996) · The Lancet · doi:10.1016/s0140-6736(96)91273-8 · Cited by 585
Association of low serum concentration of bilirubin with increased risk of coronary artery disease
Schwertner, H. A., Jackson, W. G., & Tolan, G. (1994) · Clinical Chemistry · doi:10.1093/clinchem/40.1.18 · Cited by 474
Kaplan, M., Renbaum, P., Levy-Lahad, E., Hammerman, C., Lahad, A., & Beutler, E. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.22.12128 · Cited by 345
Self-citationSTUDIES ON THE NEONATAL DEVELOPMENT OF THE GLUCURONIDE CONJUGATING 12
Brown, A. K., & Zuelzer, W. W. (1958) · Journal of Clinical Investigation · doi:10.1172/jci103613 · Cited by 269
Bosma, P. J., Chowdhury, N. R., Goldhoorn, B. G., Hofker, M. H., Elferink, R. P. J. O., Jansen, P. L. M., & Chowdhury, J. R. (1992) · Hepatology · doi:10.1002/hep.1840150531 · Cited by 198
Analysis of genes for bilirubin UDP-glucuronosyltransferase in Gilbert's syndrome
Aono, S., Keino, H., Yamada, Y., Adachi, Y., Nanno, T., Uyama, E., Koiwai, O., & Sato, H. (1995) · The Lancet · doi:10.1016/s0140-6736(95)90702-5 · Cited by 192
Population studies on Gilbert's syndrome.
Owens, D., & Evans, J. (1975) · Journal of Medical Genetics · doi:10.1136/jmg.12.2.152 · Cited by 189
Cited by
Innocenti, F., Undevia, S. D., Iyer, L., Xian Chen, P., Das, S., Kocherginsky, M., Karrison, T., Janisch, L., Ramírez, J., Rudin, C. M., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.07.173 · Cited by 964
UGT1A1*28 polymorphism as a determinant of irinotecan disposition and toxicity
Iyer, L., Das, S., Janisch, L., Wen, M., Ramírez, J., Karrison, T., Fleming, G. F., Vokes, E. E., Schilsky, R. L., & Ratain, M. J. (2002) · The Pharmacogenomics Journal · doi:10.1038/sj.tpj.6500072 · Cited by 720
Hanna, N., Bunn, P. A., Langer, C., Einhorn, L., Guthrie, T., Beck, T., Ansari, R., Ellis, P., Byrne, M., Morrison, M., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.04.8595 · Cited by 681
Dennery, P. A., Seidman, D. S., & Stevenson, D. K. (2001) · New England Journal of Medicine · doi:10.1056/nejm200102223440807 · Cited by 598
AGA technical review on the evaluation of liver chemistry tests
Green, R. M., & Flamm, S. (2002) · Gastroenterology · doi:10.1053/gast.2002.36061 · Cited by 587
UGT1A1*28 Genotype and Irinotecan-Induced Neutropenia: Dose Matters
Hoskins, J. M., Goldberg, R. M., Qu, P., Ibrahim, J. G., & McLeod, H. L. (2007) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djm115 · Cited by 469
Pharmacogenomics of human UDP-glucuronosyltransferase enzymes
Guillemette, C. (2003) · The Pharmacogenomics Journal · doi:10.1038/sj.tpj.6500171 · Cited by 425
de Man, F. M., Goey, A. K. L., van Schaik, R. H. N., Mathijssen, R. H. J., & Bins, S. (2018) · Clinical Pharmacokinetics · doi:10.1007/s40262-018-0644-7 · Cited by 421
“The incidence of this genetic variant is relatively high among Caucasians (minor allele frequency [MAF] 26–39%) and Africans/ African Americans (MAF 30–56%) [235, 236].”
BackgroundPharmacogenomics: The Inherited Basis for Interindividual Differences in Drug Response
Evans, W. E., & Johnson, J. A. (2001) · Annual Review of Genomics and Human Genetics · doi:10.1146/annurev.genom.2.1.9 · Cited by 415
Kadakol, A., Ghosh, S. S., Sappal, B. S., Sharma, G., Chowdhury, J. R., & Chowdhury, N. R. (2000) · Human Mutation · doi:10.1002/1098-1004(200010)16:4<297::aid-humu2>3.0.co;2-z · Cited by 387
Sugatani, J., Kojima, H., Ueda, A., Kakizaki, S., Yoshinari, K., Gong, Q.-H., Owens, I. S., Negishi, M., & Sueyoshi, T. (2001) · Hepatology · doi:10.1053/jhep.2001.24172 · Cited by 381
PharmGKB summary: pathways of acetaminophen metabolism at the therapeutic versus toxic doses
Mazaleuskaya, L. L., Sangkuhl, K., Thorn, C. F., FitzGerald, G. A., Altman, R. B., & Klein, T. E. (2015) · Pharmacogenetics and Genomics · doi:10.1097/fpc.0000000000000150 · Cited by 379
Abundant Raw Material for Cis-Regulatory Evolution in Humans
Rockman, M. V., & Wray, G. A. (2002) · Molecular Biology and Evolution · doi:10.1093/oxfordjournals.molbev.a004023 · Cited by 376
The role of hepatic and extrahepatic UDP-glucuronosyltransferases in human drug metabolism*†
Fisher, M. B., Paine, M. F., Strelevitz, T. J., & Wrighton, S. A. (2001) · Drug Metabolism Reviews · doi:10.1081/dmr-120000653 · Cited by 375
The UDP-Glycosyltransferase (UGT) Superfamily: New Members, New Functions, and Novel Paradigms
Meech, R., Hu, D. G., McKinnon, R. A., Mubarokah, S. N., Haines, A. Z., Nair, P. C., Rowland, A., & Mackenzie, P. I. (2019) · Physiological Reviews · doi:10.1152/physrev.00058.2017 · Cited by 368
Caraco, Y., Blotnick, S., & Muszkat, M. (2008) · Clinical Pharmacology & Therapeutics · doi:10.1038/sj.clpt.6100316 · Cited by 360
Irinotecan, a key chemotherapeutic drug for metastatic colorectal cancer
Fujita, K.-I. (2015) · World Journal of Gastroenterology · doi:10.3748/wjg.v21.i43.12234 · Cited by 323
Lin, J.-P., O’Donnell, C. J., Schwaiger, J. P., Cupples, L. A., Lingenhel, A., Hunt, S. C., Yang, S., & Kronenberg, F. (2006) · Circulation · doi:10.1161/circulationaha.106.633206 · Cited by 314
Wu, B., Kulkarni, K., Basu, S., Zhang, S., & Hu, M. (2011) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.22568 · Cited by 309
Chapter 6: Estrogen Metabolism by Conjugation
Raftogianis, R., Creveling, C., Weinshilboum, R., & Weisz, J. (2000) · JNCI Monographs · doi:10.1093/oxfordjournals.jncimonographs.a024234 · Cited by 297
Inherited disorders of bilirubin metabolism
Bosma, P. J. (2003) · Journal of Hepatology · doi:10.1016/s0168-8278(02)00359-8 · Cited by 279
Relevance of Different UGT1A1 Polymorphisms in Irinotecan-Induced Toxicity
Rouits, E., Boisdron-Celle, M., Dumont, A., Guérin, O., Morel, A., & Gamelin, E. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-03-0548 · Cited by 276
Comprehensive Pharmacogenetic Analysis of Irinotecan Neutropenia and Pharmacokinetics
Innocenti, F., Kroetz, D. L., Schuetz, E., Dolan, M. E., Ramírez, J., Relling, M., Chen, P., Das, S., Rosner, G. L., & Ratain, M. J. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.20.6300 · Cited by 262
Carlini, L. E., Meropol, N. J., Bever, J., Andria, M. L., Hill, T., Gold, P., Rogatko, A., Wang, H., & Blanchard, R. L. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.1226.11.3 · Cited by 262
Mechanism of indinavir-induced hyperbilirubinemia
Zucker, S. D., Qin, X., Rouster, S. D., Yu, F., Green, R. M., Keshavan, P., Feinberg, J., & Sherman, K. E. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.231140698 · Cited by 262
GLUCURONIDATION AND THE UDP-GLUCURONOSYLTRANSFERASES IN HEALTH AND DISEASE
Wells, P. G., Mackenzie, P. I., Roy Chowdhury, J., Guillemette, C., Gregory, P. A., Ishii, Y., Hansen, A. J., Kessler, F. K., Kim, P. M., Roy Chowdhury, N., et al. (2004) · Drug Metabolism and Disposition · doi:10.1124/dmd.32.3.281 · Cited by 260
Pharmacokinetic variability of anticancer agents
Undevia, S. D., Gomez-Abuin, G., & Ratain, M. J. (2005) · Nature Reviews Cancer · doi:10.1038/nrc1629 · Cited by 258
SAI, K. (2004) · Clinical Pharmacology & Therapeutics · doi:10.1016/j.clpt.2004.01.010 · Cited by 257
Zucker, S. D., Horn, P. S., & Sherman, K. E. (2004) · Hepatology · doi:10.1002/hep.1840400412 · Cited by 253
Risk Factors for Severe Hyperbilirubinemia in Neonates
Huang, M.-J., Kua, K.-E., Teng, H.-C., Tang, K.-S., Weng, H.-W., & Huang, C.-S. (2004) · Pediatric Research · doi:10.1203/01.pdr.0000141846.37253.af · Cited by 242
Stingl, J. C., Bartels, H., Viviani, R., Lehmann, M. L., & Brockmöller, J. (2014) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2013.09.002 · Cited by 178
Review of Opioid Pharmacogenetics and Considerations for Pain Management
Owusu Obeng, A., Hamadeh, I., & Smith, M. (2017) · Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.1986 · Cited by 171
Molecular genetic basis of Gilbert's syndrome
Burchell, B., & Hume, R. (1999) · Journal of Gastroenterology and Hepatology · doi:10.1046/j.1440-1746.1999.01984.x · Cited by 170
del Giudice, E. M., Perrotta, S., Nobili, B., Specchia, C., d’Urzo, G., & Iolascon, A. (1999) · Blood · doi:10.1182/blood.v94.7.2259.419k42_2259_2262 · Cited by 159
Diagnostic criteria and contributors to Gilbert’s syndrome
Wagner, K.-H., Shiels, R. G., Lang, C. A., Seyed Khoei, N., & Bulmer, A. C. (2018) · Critical Reviews in Clinical Laboratory Sciences · doi:10.1080/10408363.2018.1428526 · Cited by 138
Bancone, G., Gornsawun, G., Peerawaranun, P., Penpitchaporn, P., Paw, M. K., Poe, D. D., Win, D., Cicelia, N., Mukaka, M., Archasuksan, L., et al. (2022) · PLOS Global Public Health · doi:10.1371/journal.pgph.0000475 · Cited by 14
“The prevalence of UGT1A128 is around 30% in Caucasians, between 40% and 56% in African Americans, and less than 15% in Asian populations [12].”
Background
Metadata
- Authors
- Beutler, E., Gelbart, T., & Demina, A.
- Venue
- Proceedings of the National Academy of Sciences
- Published
- 1998-07-07
- Volume
- 95
- Issue
- 14
- Pages
- 8170-8174
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- OpenAlex
- W2107262592
- Cited by
- 853
- References
- 23
- FWCI
- 22.85
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.